These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36928351)

  • 1. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
    O'Donnell P; Dong C; Murthy V; Asgharnejad M; Du X; Summerfelt A; Lu H; Xu L; Wendland JR; Dunayevich E; Buhl DL; Litman R; Hetrick WP; Hong LE; Rosen LB
    Neuropsychopharmacology; 2023 Jun; 48(7):1052-1059. PubMed ID: 36928351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia.
    Fradley R; Goetghebeur P; Miller D; Burley R; Almond S; Gruart I Massó A; Delgado García JM; Zhu B; Howley E; Neill JC; Grayson B; Gaskin P; Carlton M; Gray I; Serrats J; Davies CH
    Neurochem Res; 2023 Oct; 48(10):3027-3041. PubMed ID: 37289348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia.
    Murthy V; Hanson E; DeMartinis N; Asgharnejad M; Dong C; Evans R; Ge T; Dunayevich E; Singh JB; Ratti E; Galderisi S
    Schizophr Res; 2024 Jun; 270():249-257. PubMed ID: 38943928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine.
    Sehatpour P; Iosifescu DV; De Baun HM; Shope C; Mayer MR; Gangwisch J; Dias E; Sobeih T; Choo TH; Wall MM; Medalia A; Saperstein AM; Kegeles LS; Girgis RR; Carlson M; Kantrowitz JT
    Biol Psychiatry; 2023 Jul; 94(2):164-173. PubMed ID: 36958998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
    Kantrowitz JT; Epstein ML; Lee M; Lehrfeld N; Nolan KA; Shope C; Petkova E; Silipo G; Javitt DC
    Schizophr Res; 2018 Jan; 191():70-79. PubMed ID: 28318835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia.
    Wang H; Norton J; Xu L; DeMartinis N; Sen R; Shah A; Farmer J; Lynch D
    Ann Clin Transl Neurol; 2021 Jun; 8(6):1343-1352. PubMed ID: 34018342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
    Kantrowitz JT; Epstein ML; Beggel O; Rohrig S; Lehrfeld JM; Revheim N; Lehrfeld NP; Reep J; Parker E; Silipo G; Ahissar M; Javitt DC
    Brain; 2016 Dec; 139(Pt 12):3281-3295. PubMed ID: 27913408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
    Sehatpour P; Javitt DC; De Baun HM; Carlson M; Beloborodova A; Margolin DH; Carlton MBL; Brice NL; Kantrowitz JT
    Neuropsychopharmacology; 2022 Feb; 47(3):711-718. PubMed ID: 34667294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Light GA; Zhang W; Joshi YB; Bhakta S; Talledo JA; Swerdlow NR
    Neuropsychopharmacology; 2017 Dec; 42(13):2633-2639. PubMed ID: 28425497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
    Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
    Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials.
    Chang CH; Lane HY; Tseng PT; Chen SJ; Liu CY; Lin CH
    J Psychopharmacol; 2019 Apr; 33(4):436-448. PubMed ID: 30730250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.
    Strick CA; Li C; Scott L; Harvey B; Hajós M; Steyn SJ; Piotrowski MA; James LC; Downs JT; Rago B; Becker SL; El-Kattan A; Xu Y; Ganong AH; Tingley FD; Ramirez AD; Seymour PA; Guanowsky V; Majchrzak MJ; Fox CB; Schmidt CJ; Duplantier AJ
    Neuropharmacology; 2011; 61(5-6):1001-15. PubMed ID: 21763704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.
    Sershen H; Hashim A; Dunlop DS; Suckow RF; Cooper TB; Javitt DC
    Neurochem Res; 2016 Feb; 41(1-2):398-408. PubMed ID: 26857796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
    Lin CY; Liang SY; Chang YC; Ting SY; Kao CL; Wu YH; Tsai GE; Lane HY
    World J Biol Psychiatry; 2017 Aug; 18(5):357-368. PubMed ID: 26691576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of glycine on auditory mismatch negativity in schizophrenia.
    Greenwood LM; Leung S; Michie PT; Green A; Nathan PJ; Fitzgerald P; Johnston P; Solowij N; Kulkarni J; Croft RJ
    Schizophr Res; 2018 Jan; 191():61-69. PubMed ID: 28602646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
    Lin CH; Chen PK; Chang YC; Chuo LJ; Chen YS; Tsai GE; Lane HY
    Biol Psychiatry; 2014 May; 75(9):678-85. PubMed ID: 24074637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug discovery strategies and the preclinical development of D-amino-acid oxidase inhibitors as antipsychotic therapies.
    Szilágyi B; Ferenczy GG; Keserű GM
    Expert Opin Drug Discov; 2018 Oct; 13(10):973-982. PubMed ID: 30220232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
    Kantrowitz JT; Swerdlow NR; Dunn W; Vinogradov S
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2018 Jul; 3(7):581-590. PubMed ID: 29656951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.